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OBJECTIVES: To determine the healthcare costs of acute
and chronic pain associated with herpes zoster.
DESIGN: Retrospective cohort analysis.
SETTING: Inpatient and outpatient care.
PARTICIPANTS: Patients were selected from Medicare,
commercial insurance, and Medicaid claims databases if
they had a diagnosis of herpes zoster or postherpetic neu-
ralgia (PHN) or were prescribed analgesics after a diagnosis
of herpes zoster (possible PHN) and were matched to con-
trols for demographic and clinical factors using propensity
scores.
MEASUREMENTS: One-year excess healthcare expendi-
tures attributable to herpes zoster pain or PHN were cal-
culated for inpatient, outpatient, and prescription drug
services.
RESULTS: For the Medicare cohort, the average excess cost
per patient was $1,300 in the year after a diagnosis of herpes
zoster with 30 days or fewer of analgesic use and ranged
from $2,200 to $2,300 per patient with PHN or possible
PHN. Patients with possible PHN were 53% more prevalent
than patients with PHN in the Medicare cohort and ac-
counted for half of all excess expenditures. Findings were
similar in the younger cohorts with commercial insurance
and Medicaid except that costs attributable to PHN and
possible PHN were higher, and patients with possible PHN
were three to five times as prevalent as patients with PHN.
CONCLUSION: Healthcare costs associated with PHN
were substantially greater than those associated with herpes
zoster pain that resolved within 30 days. The data suggest
that as many as 80% of patients with PHN may not be
diagnosed with PHN and that these patients account for at
least half of PHN expenditures. J Am Geriatr Soc 55:1168–
1175, 2007.
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Reactivation of varicella-zoster virus and its spread froma sensory ganglion to the corresponding dermatome
causes herpes zoster (shingles).1,2 Herpes zoster occurs an-
nually in approximately one million people in the United
States, during the lifetimes of up to 30% of the population,
and in as many as 50% of those living until 85 years of
age.1,3–8 The appearance of a characteristic unilateral
dermatomal rash with localized pain marks the onset of
herpes zoster in nearly all patients. Pain persists after rash
healing in a substantial percentage of patients with herpes
zoster, although the precise figure depends on age and other
risk factors. A recent observational study of patients with
herpes zoster (more than half aged 50) presenting to
family physicians in England reported that pain persisted in
38% at 6 weeks, 27% at 12 weeks, 16% at 6 months, and
9% at 1 year.9
The results of recent research provide support for a
distinction between three phases of pain associated with
herpes zosterFacute pain occurring within 30 days after
rash onset; postherpetic neuralgia (PHN), defined as pain
that persists 120 days or more after rash onset; and sub-
acute herpetic neuralgia (SHN), pain that persists beyond
30 days but resolves before the diagnosis of PHN is
made.10–12 PHN is the most common and most feared
complication of herpes zoster in immunocompetent pa-
tients, and estimates of its prevalence in the United States
range from 500,000 to 1,000,000.13,14 In one large sample,
12.5% of patients with herpes zoster developed PHN de-
fined as pain 90 days after rash onset of at least 3 on a pain
intensity scale of 0 to 10.8
It was recently found that the average costs associated
with PHN and SHN ranged from $2,700 to $9,300 in the
year after diagnosis, depending on the patient’s type of in-
surance.15 The absence of data on the costs of acute pain in
patients with herpes zoster (pain that resolved within 30
days after the diagnosis), modest sample sizes in some
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groups, and the need to extrapolate Medicaid costs to allow
comparison with other insurance types limited this analysis.
The objectives of the present analyses are to evaluate the
healthcare costs associated with acute and chronic pain in
patients with herpes zoster in an expanded database that
addresses these limitations. Accurate determination of the
healthcare expenses associated with herpes zoster will in-
crease the validity of cost-effectiveness analyses of treat-
ments for PHN16 and of strategies to prevent herpes zoster
and PHN,17 for example, zoster vaccination.8
METHODS
This study is a retrospective cohort analysis. Excess health-
care costs in patients with herpes zoster acute pain, PHN,
or SHN were calculated by comparing expenditures for
cohorts of patients with these painful conditions with
expenditures of control groups without these conditions
who were propensity score matched on demographic char-
acteristics and comorbidities to the patients with pain
to eliminate measurable differences between the groups.
Estimates are provided for those with Medicare, commer-
cial insurance, and Medicaid separately.
Study Population
The data for this study came from Thomson-Medstat’s
MarketScan suite of databases (www.medstat.com), which
was chosen, because it contains individual-level healthcare
claims information from Medicare, Medicaid, large em-
ployers, and managed care organizations and captures the
full continuum of care for nearly 28 million covered lives in
all settings, including physician office visits; hospital stays;
retail, mail order, and specialty pharmacies; and any insured
services managed by specialty vendors. It contains complete
information on outpatient prescriptions and high-quality
coding and has strong longitudinal tracking at the patient
level, with the capability of following more than half of
the individuals in MarketScan for 3 years. Three separate
databases were used in this study: the Medicare, Commer-
cial Claims and Encounters, and Medicaid databases. The
Medicare database contains the healthcare experience
of approximately one million individuals with Medicare
supplemental insurance paid for by employers. The Med-
icare-covered portion of payment (represented as Coordi-
nation of Benefits Amount) and the employer-paid portion
are included in this database. The commercial database
contains the healthcare experience of approximately 8 mil-
lion employees and their dependents (annually) covered
under a variety of fee-for-service and capitated health plans,
including preferred provider organizations, point of service
plans, indemnity plans, and health maintenance organiza-
tions. The Medicaid database contains the pooled health-
care experience of approximately 10 million Medicaid
enrollees from several geographically dispersed states. All
these databases link enrollment and medical claims for
inpatient, outpatient, and outpatient prescription drug
services for each patient.
Patients were considered to have herpes zoster acute
pain if they had a healthcare claim with primary diagnosis
of herpes zoster (International Classification of Diseases,
10th Revision (ICD-10) 053.9x, 053.0x, 053.10, 053.11,
053.2x, 053.7x, 053.8x) and had received o31 days of
analgesic medication starting within 30 days after the herpes
zoster diagnosis. Medications considered analgesics were
those commonly used during the study period, whether
appropriately or not, in the treatment of PHN and other
neuropathic pain conditions, including gabapentin, lido-
caine patch 5%, opioid analgesics (e.g., buprenorphine,
butorphanol, codeine, dezocine, dihydrocodeine, fentanyl,
hydrocodone, hydromorphone, levorphanol, meperidine,
methadone, morphine sulfate, nalbuphine, oxycodone,
oxymorphone, pentazocine, propoxyphene) alone and
in combination with other medications, tramadol, tri-
cyclic antidepressants (TCAs; amitriptyline, amoxapine,
clomipramine, desipramine, doxepin, imipramine, nor-
triptyline, protriptyline, trimipramine), other anticonvul-
sants (lamotrigine, oxcarbazepine), other antidepressants
(bupropion, citalopram, escitalopram, fluoxetine, fluvoxa-
mine, isocarboxazid, maprotiline, mirtazepine, nefazodone,
paroxetine, phenelzine, sertraline, tranylcypromine, trazo-
done, venlafaxine), and benzodiazepines (alprazolam,
chlordiazepoxide, clorazepate, diazepam, estazolam,
flurazepam, halazepam, lorazepam, midazolam, oxazepam,
prazepam, quazepam, temazepam, triazolam).18,19 Because
antidepressants other than TCAs and benzodiazepines
may not have been used for pain associated with herpes
zoster, considering these medications to be analgesics may
have introduced a misclassification bias; for this reason,
we performed sensitivity analyses that excluded these
medications.
Patients were considered to have PHN if they had a
healthcare claim with a primary diagnosis of PHN (ICD-10
053.12, 053.13, 053.19). Because the concept of subacute
herpetic neuralgia has only been validated in the past sev-
eral years,10–12 it is likely that this group includes patients
with SHN who were diagnosed with PHN.
Patients were considered to have possible PHN if they
had a healthcare claim with a primary diagnosis of herpes
zoster (ICD-10 053.9x, 053.0x, 053.10, 053.11, 053.2x,
053.7x, 053.8x) and had received more than 30 days of
analgesic medication starting within 30 days after the her-
pes zoster diagnosis. As above, medications considered to
be analgesics in the primary analysis were those commonly
used during the study period, whether appropriately or not,
in the treatment of PHN and other neuropathic pain con-
ditions.18,19 Because of their persisting use of analgesic
medications after their diagnosis of herpes zoster, it is likely
that the possible PHN group consists of a mixture of pa-
tients with PHN and SHN whose herpes zoster diagnoses
were not revised to reflect their persistent pain.
The date of the herpes zoster or PHN diagnosis that
met the above criteria was considered the index event. The 6
months preceding the index date was the pre-period, which
was used for propensity matching, and the 12 months after
the index date was the post-period, from which expenditure
data were derived. The index date was between July 1,
2001, and December 31, 2003.
Patients were only included in the study once. If a pa-
tient was eligible to be in more than one of the pain cohorts,
they were assigned based on the following hierarchy: PHN,
possible PHN, herpes zoster (i.e., if a patient with herpes
zoster later developed PHN, they were included in the PHN
cohort). It is important to emphasize that all prescription
medication claims are included in the Medicare, commer-
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cial insurance, and Medicaid databases and that the only
way that patients could have obtained prescription analge-
sics without being identified would have been if they did not
use their insurance and paid cash for the prescription.
Patients were excluded from the study if they were not
continuously enrolled from the pre-period through the post-
period or if at any time during the study they were pregnant
or insured under a capitated insurance plan. Pregnant pa-
tients were excluded, because certain pain medications may
be contraindicated during pregnancy. Healthcare payment
information on capitated insurance claims is often missing
or not representative of the services provided; thus patients
with capitated coverage were excluded.
A random sample of patients without diagnoses of her-
pes zoster and PHN were the control cohorts. Separate
control groups were selected for each pain cohort (herpes
zoster, possible PHN, and PHN) and insured group (Med-
icare, commercial, and Medicaid). The control groups were
nine times as large as the corresponding pain cohorts and
met the same exclusion criteria. The index date for the
controls was randomly assigned from the appropriate pain
cohort.
Measurements
Patient demographic characteristics included age at index
diagnosis and sex. A residence variable (urban vs rural) was
also included and defined based on residence within a me-
tropolitan statistical area. The region of the country where
the patient resided was also tabulated for the Medicare and
commercial patients (this information was not available for
Medicaid patients). The regions included the northeast,
north central, south, and west. Because patients’ index
dates could vary from 2001 to 2003, this was controlled for
by including binary indicators for each year. For the Med-
icaid patients, race/ethnicity was also available and con-
sisted of African American, American Indian or Alaskan
native, Asian or Pacific Islander, Caucasian, Hispanic, and
other/missing.
To control for overall medical comorbidity, the Charl-
son Comorbidity Index (CCI) score in the pre-period was
used. The CCI score is a measure of the burden of comorbid
illness that can be calculated easily with claims data. Higher
CCI values indicate a higher probability of death or major
disability due to comorbid illness.20,21
To control for concomitant psychiatric conditions, a
psychiatric diagnostic group (PDG) variable was used that
measures the number of major psychiatric conditions for
which a patient received treatment in the pre-period.22 This
is based on ICD-9 diagnosis codes present on claims, which
are analogous to the major diagnostic categories used in the
diagnosis-related groups classification system.
Medicare and commercial patients were divided into
those covered by traditional indemnity plans and those
covered by managed care plans. Managed care plans in-
cluded point of service and preferred provider service plans.
The outcome variable of interest in this study was an-
nual healthcare expenditures, which were measured for
each patient in the post-period. Excess healthcare costs
were estimated as the difference in average annual health-
care expenditures between the pain cohorts and the
matched control groups. Expenditures are reported in
2004 dollars.
Data Analyses
Descriptive analyses were used to compare the pain cohorts
with their respective control groups before and after match-
ing. Chi-square tests were used to compare binary indica-
tors across the cohorts, and Student t tests were used for the
continuous variables.
A key problem with observational studies is the lack of
randomization in assigning individuals to groups. Because
of this, the existence of confounding factors may bias results
from descriptive analyses. Propensity score matching was
developed for adjusting such confounding factors. The
main purpose of matching is to reduce selection bias by
improving the balance between groups. Propensity score
matching employs the predicted probability of group mem-
bership based on observed predictors. For example, given
two patients, one in a pain cohort and one in its control
group with the same (or a similar) propensity score, these
patients can be considered to be randomly assigned to each
group.23
The control patients were matched to pain cohorts ac-
cording to the predicted probability of being in that pain
cohort. This probability was estimated for each patient
based on a logistic regression analysis that controlled for
patient demographic characteristics (age, sex, insurance
type, region, urban residency, and index year, and in addi-
tion, race for the Medicaid patients) and overall comorbid-
ities (CCI and PDG) in the pre-period. This was done
separately for each pain cohort and each insured group
(Medicare, commercial, Medicaid), creating a total of nine
pain cohort and control group pairs. Patients were matched
using a nearest-neighbor, within-caliber, one-to-one ap-
proach.24 Patients who were not matched were eliminated
from the sample.
Consistent with previous studies,25 a second-stage re-
gression was estimated to control for remaining significant
differences between the cohorts on the matching variables.
Specifically, the second-stage regression used total health-
care expenditures in the post-period as the dependent
variable and the same independent variables used in the
matching. Because healthcare expenditures are often
skewed, a generalized linear model was used. When nor-
mality does not hold, generalized linear models use quasi-
maximum likelihood estimation rather than maximum
likelihood estimation. These estimators are robust to
distributional misspecification, that is, if the conditional
mean is correctly specified, quasi-maximum likelihood con-
sistently estimates the parameters regardless of distribution.
Although benzodiazepines and antidepressants other
than TCAs are used to treat patients with PHN and other
neuropathic pain conditions,19 their use in neuropathic pain
is not evidence based and may not be as widespread as
treatments for which there is evidence of efficacy.18 For this
reason, sensitivity analyses were conducted in which ben-
zodiazepines and ‘‘other antidepressants’’ were deleted
from the list of analgesics used for determining which pa-
tients with herpes zoster pain to include in the study. All of
the models were rerun, and the results of these sensitivity
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analyses were compared with the primary analyses that in-
cluded benzodiazepines and ‘‘other antidepressants.’’
RESULTS
Post-matching demographic and clinical characteristics of
patients and controls are shown in Table 1. (Additional pre-
and post-matching characteristics for each of the pain and
control cohorts are available from the first author.) After
matching, patients in the Medicare group were approxi-
mately 25 years older than patients in the commercial and
Medicaid groups. Medicare patients also had higher CCI
scores than those with commercial insurance and lower
mean numbers of PDGs than those with Medicaid.
For all three types of insurance, patients with herpes
zoster acute pain were well matched with their control
groups except that CCI scores were higher in the pain
cohorts than in their respective control groups (Table 1).
Patients with PHN and possible PHN were generally well
matched with their control groups for all insurance types
except that CCI scores and number of PDGs were higher in
the pain cohorts than in their respective control groups
(Table 1).
Multivariate Results
The expenditure data for each type of pain for the three
insurance types are presented in Table 2. Exact coefficients
and marginal effects for the generalized linear models are
available from the first author.
Herpes Zoster Acute Pain
The annual excess healthcare costs per patient associated
with herpes zoster acute pain were $1,298 in the Medicare
sample (Po.001). Excess expenditure estimates were sim-
ilar in the commercial sample but were 42% lower in the
Medicaid sample (Table 2). For each insurance type, greater
comorbidity, as assessed according to the CCI and PDG
scores, and older age were associated with greater expen-




















n 2,554 2,554 1,722 1,722 2,634 2,634
Age 75.2 75.2 .80 77.1 77.2 .58 75.9 76.1 .43
Female, % 61.1 62.2 .42 66.0 66.4 .80 70.3 72.0 .18
Insurance type, %
Missing/unknown 0.08 0.00 .16 0.00 0.12 .16 0.11 0.00 .08
Indemnity 57.7 62.3 .001 58.2 59.7 .37 59.1 61.6 .06
POS or PPO 42.2 37.7 .001 41.8 40.2 .33 40.8 38.4 .08
Health status
CCI 1.41 1.27 .009 1.70 1.54 .01 1.85 1.57 o.001
PDGs 0.07 0.08 .36 0.17 0.11 .001 0.22 0.12 o.001
Commercial insurance
Demographics
n 4,696 4,696 1,037 1,037 3,285 3,285
Age 48.8 48.8 .94 52.8 53.0 .75 51.7 52.2 .04
Female, % 60.3 60.1 .88 66.3 66.9 .78 73.2 72.8 .68
Insurance type
Missing/unknown 0.06 0.13 .32 0.39 0.19 .41 0.09 0.06 .66
Indemnity 19.5 19.8 .74 22.5 21.6 .63 24.0 23.5 .60
POS or PPO 80.5 80.1 .68 77.1 78.2 .56 75.9 76.5 .58
Health status
CCI 0.57 0.47 o.001 0.87 0.70 .003 0.93 0.69 o.001
PDGs 0.12 0.09 .003 0.24 0.14 o.001 0.40 0.25 o.001
Medicaid
Demographics
n 1,407 1,407 373 373 1,872 1,872
Age 45.1 45.8 .33 50.3 53.9 .003 49.4 51.5 o.001
Female, % 62.0 62.5 .76 65.4 63.5 .59 71.4 67.5 .01
Health status
CCI 1.28 1.00 o.001 1.53 1.06 o.001 1.92 1.48 o.001
PDGs 0.40 0.44 .15 0.74 0.57 .020 1.18 0.91 o.001
PHN 5 postherpetic neuralgia; POS 5 point of service plan; PPO 5 preferred provider organization plan; CCI 5 Charlson Comorbidity Index; PDGs 5 psy-
chiatric diagnosis group diagnoses.
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ditures (P4.001), although the magnitude of the effect for
age was modest.
PHN and Possible PHN
For Medicare patients, the annual excess healthcare costs
associated with PHN and possible PHN were $2,159 and
$2,292, respectively (Po.001). Based on these estimates,
excess expenditures for patients with PHN and possible
PHN were more than twice as high in patients with com-
mercial insurance and Medicaid as in Medicare patients
(Table 2).
For each insurance type, higher CCI scores and greater
number of PDGs were associated with greater expenditures
in patients with PHN and possible PHN (Po.001). The
majority of patients with possible PHN were taking anal-
gesics between 4 and 6 months after the diagnosis of herpes
zoster: 79.2% in the Medicare sample (vs 32.6% of con-
trols), 82.9% in the commercial sample (vs 30.6% of
controls), and 88.5% in the Medicaid sample (vs 49.1%
of controls).
In the Medicare sample, 53% more patients had pos-
sible PHN than had PHN (Table 1). Patients with possible
PHN were also more prevalent in the commercial and
Medicaid samples. Because it was prevalent and expensive
to treat, possible PHN accounted for the majority of total
expenditures (Figure 1).
Expenditure Components
Table 3 displays the percentages of the total expenditures
attributable to different types of care for each pain category
and insurance. In all of the cohorts, the majority of expenses
are not directly attributable to herpes zoster or mental
health (but occur in the ‘‘other’’ category). For each insur-
ance type, expenditures for prescriptions are substantially
greater for patients with PHN and possible PHN than for
patients with herpes zoster with acute pain. For patients
with Medicare and commercial insurance, approximately
half of all healthcare payments represent outpatient non-
emergency department claims.
Sensitivity Analyses
When benzodiazepines and ‘‘other antidepressants’’ were
deleted from the list of analgesics used for determining
which patients with herpes zoster pain to include in the
study, the numbers of Medicare patients in the herpes zoster
acute pain and possible PHN cohorts decreased 12% and
10%, respectively, and the respective expenditure estimates
decreased 32% and 20%. The numbers of patients in the
different commercial insurance and Medicaid cohorts de-
creased 12% to 16%, with the expenditure estimates falling
40% to 47% for commercial patients and 69% to 87% for
Medicaid patients (specific results for each of the pain and
control cohorts are available from the first author). The
results for the PHN models did not change, because med-
ication use was not a criterion for being included in this
cohort.
DISCUSSION
The results indicate that annual healthcare costs associated
with PHN range from $2,159 to $5,387 and are much
greater than the healthcare costs associated with acute pain
in patients with herpes zoster, which range from $757 to
$1,313. Patients who were not diagnosed with PHN but
who were classified as having possible PHN generated most
of the excess expenditures. These patients had diagnoses of
herpes zoster but had received more than 30 days of anal-
gesic medication starting within 30 days after their diag-
nosis with herpes zoster. Their annual healthcare costs
ranged from $2,292 to $5,742 and were similar to those of
the patients who were diagnosed with PHN.
The total costs of care and the components of the costs
of care (Table 3) associated with PHN and possible PHN
were remarkably similar. Furthermore, 79.2% to 88.5% of
the patients with possible PHN were taking analgesics more
than 3 months after their diagnosis with herpes zoster.
Considered together, these data suggest that a large
Table 2. Total Excess Expenditures Derived from the Generalized Linear Models
Pain Type
Medicare Commercial Medicaid
Expenditures P-Value Expenditures P-Value Expenditures P-Value
Herpes zoster $1,298 o.001 $1,313 o.001 $757 .09
PHN $2,159 o.001 $5,387 o.001 $5,112 o.001
Possible PHN $2,292 o.001 $5,742 o.001 $5,178 o.001













PHN = postherpetic neuralgia;




Figure 1. Percentages of all expenditures accounted for by dif-
ferent pain conditions (reflects costs per patient and number of
patients in each category).
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percentage of the patients who were classified with possible
PHN probably had undiagnosed PHN, that is, these pa-
tients had developed PHN but had not had their diagnoses
changed from herpes zoster to reflect the persistence of their
pain. It is important to recognize that the group of patients
with possible PHN was much larger than the group with
PHN and that much of the total healthcare expenditure
burden associated with persisting pain in patients with her-
pes zoster would be missed if patients without a diagnosis of
PHN but with a diagnosis of herpes zoster were excluded
from consideration. The proportion of patients with pos-
sible PHN was somewhat lower in the Medicare group,
which suggests that Medicare patients with persisting pain
are more likely to be diagnosed with PHN than patients
with commercial insurance or Medicaid (Table 1). This
could reflect greater familiarity with PHN among providers
of Medicare patients or greater expectation of PHN in older
patients. Future research must consider the effect of under-
diagnosis of PHN not only on estimates of healthcare costs,
but also on the adequacy of clinical care in the community.
In these data, older age was associated with higher ex-
penditures for many of the pain cohorts, although the mag-
nitude of this effect was modest. However, even though the
average Medicare patient was considerably older than the
average patient with commercial insurance or Medicaid,
Medicare expenditures were generally lower than commer-
cial insurance or Medicaid expenditures for the cohorts
with PHN and possible PHN. The explanation for this is
unclear but could involve higher background healthcare
expenditures in the Medicare control groups and possibly
greater out-of-pocket expenses for Medicare patients.
Patients with PHN suffer from physical disability and
emotional distress and have greatly increased healthcare
utilization as a result of their chronic pain.26–28 In addition,
acute pain in herpes zoster has been shown to have adverse
effects on physical and emotional functioning.29,30 On the
basis of a cost-utility analysis conducted for England and
Wales,31 the total societal costs of herpes zoster and PHN in
the United States could be estimated as approximately
$1.7 billion per year, which would include physician visits,
hospitalizations, work loss, and household expenditures.
The percentages of these costs that are attributable sepa-
rately to herpes zoster and PHN cannot be estimated from
this study. In studies conducted in the 1990s, the healthcare
costs of PHN were estimated to be as high as $3,250 per
year (converted to 2004 dollars).26,32–35 A recent study of
the economic costs of neuropathic pain, including PHN,
reported that calendar year 2000 healthcare charges were
higher in patients with neuropathic pain ($17,355) than in
matched controls ($5,715) in a sample of patients drawn
from private healthcare plans in the United States.36 Most
recently, using a smaller set of data with no information on
acute pain during herpes zoster, markedly variable esti-
mates of excess healthcare costs associated with PHN (in-
cluding SHN) were found that ranged from $2,696 to
$9,310 during the first year, depending on insurance type.15
The present study is the first assessment of healthcare
costs associated with the acute pain of herpes zoster and the
chronic pain of PHN in the United States. The present
analysis extends earlier findings by providing more-precise
estimates of expenditures for each of three insurance types;
separate estimates for patients with herpes zoster acute
pain, patients diagnosed with PHN, and patients who re-
ceived more than 30 days of analgesics after a diagnosis of
herpes zoster, who appear to be undiagnosed patients with
PHN; and quantification of the relative frequency of these
different types of pain after a diagnosis of herpes zoster and
their relative contributions to the overall cost burden of
pain associated with herpes zoster.
The incidence of herpes zoster seems to have increased
in the past several decades,37 and several factors suggest
that the number of patients suffering from herpes zoster and
PHN will continue to increase. The number of individuals
at the greatest risk for herpes zosterFbecause they are
older or immunocompromisedFis expected to rise, and
older age also increases the risk of PHN.27 In addition,
recent epidemiological data38,39 are consistent with the
prediction that the incidence of herpes zoster will increase
because childhood varicella vaccination has reduced the
opportunities for subclinical immune boosting associated
with exposure to varicella-zoster virus.40–42
These analyses in the present study have several lim-
itations. Accurate categorization of insurance information
depends on correct ICD-10 coding, and it was not possible
to evaluate the accuracy of the diagnoses used. It is also
possible that cases of herpes zoster acute pain and possible
PHN could have been missed and that the costs of these
conditions underestimated if analgesics were paid for using
other means than insurance, either because of inadequate
coverage or use of over-the-counter medications. It is likely
that including patients using only over-the-counter medi-
cations would increase the number of patients classified as
having pain, but if such patients are prevalent, the resulting
Table 3. Excess Expenditures Attributable to Different




Herpes zoster acute pain
Outpatient ED claims 3 6 11
Outpatient non-ED claims 58 54  16
Inpatient 31 17 76
Prescriptions 8 23 28
PHN
Outpatient ED claims 2 2 4
Outpatient non-ED claims 48 44  21
Inpatient 22 26 35
Prescriptions 28 28 83
Possible PHN
Outpatient ED claims 3 3 3
Outpatient non-ED claims 39 41 16
Inpatient 20 18 15
Prescriptions 38 39 65
Negative percentages occur when total expenditures in the control cohort
exceed those of pain patients for a particular component of care; total per-
centages can differ from 100% because of rounding.
PHN 5 postherpetic neuralgia; ED 5 emergency department.
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estimates of per patient excess expenditures would be de-
creased; furthermore, use of milder analgesics to identify
patients with herpes zoster pain and PHN could cause mis-
classification of other types of pain, such as from headache
or arthritis. Although the results of the sensitivity analyses
suggest that the expenditure estimates for herpes zoster
acute pain and possible PHN differ depending on the med-
ications considered to be analgesics, the Medicare results
were the least affected. Furthermore, the identification of
PHN cases was based solely on ICD-10 codes, so the es-
timates of PHN-related expenditures are not dependent on
which medications were considered to be analgesics.
Propensity score matching, although powerful, cannot
account for all possible differences that might affect health-
care expenditures. For example, it is possible that the out-
comes of patients with the same observable characteristics
could vary widely because of some unobservable factors,
such as physician or practice prescribing patterns. More-
over, only direct insurance expenditures were measured,
which underestimates the total cost to society of herpes
zoster pain. It is likely that acute and chronic pain in
patients with herpes zoster are associated with significant
out-of-pocket expenses and additional societal costs,
such as lost work time, as well as substantial impairment
in quality of life, none of which are included in the
present estimates and all of which would increase the over-
all costs of herpes zoster.43 Finally, the estimates of health-
care expenditures capture excess expenses only during the
first year after a diagnosis of herpes zoster; the total cost
of care delivered in subsequent years therefore remains
unknown.
Our results can provide a basis for cost-effectiveness
analyses16 of existing treatments for PHN.44 Because many
patients with PHN are completely or partially refractory to
these treatments,45 the development of interventions to
prevent herpes zoster and PHN has become a research pri-
ority. The data from the current study can also be used in
cost-effectiveness analyses of such preventive interven-
tions,17,46 which include vaccination of older individuals8
and antiviral therapy and other treatments designed to re-
duce the risk of PHN in patients with herpes zoster.47
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